---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-025013"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:29:58.502870+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lixte Biotechnology announces $3.5M registered direct offering at $6.00/share with warrants

## Summary
- Issued 583,334 shares (or equivalents) at $6.00/share plus warrants for 583,334 shares at $6.00, expiring 5 years.
- Gross proceeds ~$3.5M; placement agent A.G.P./Alliance Global Partners receives 6.0% fee and warrants at $6.60.
- Common stock offered via effective shelf registration S-3 (No. 333-252430); warrants issued in private placement under Section 4(a)(2).
- Closing expected July 20, 2023; 90-day lockup on further sales and 180-day prohibition on variable rate transactions.

## SEC filing metadata
- accession: 0001493152-23-025013
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/0001493152-23-025013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-025013
- JSON: https://secwatch.observer/filing/0001493152-23-025013.json
- Plain text: https://secwatch.observer/filing/0001493152-23-025013.txt

## Key facts
- Material Agreements
  LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Securities Purchase Agreement valued at approximately $3,500,000 (effective 2023-07-18).
  - Action: entry
  - Agreement: equity purchase
  - Value: approximately $3,500,000
  - Effective: 2023-07-18
  source text: On July 18, 2023, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “Registered Offering”), 583,334 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof), and common warrants to purchase up to 583,334 shares of common stock in a concurrent private placement, at a purchase price of $6.00 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000149315223025013/0001493152-23-025013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.